Last Update: Oct 31, 2025
A Phase 2, Open-label, Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel in Patients With Active, Refractory Systemic Lupus Erythematosus (SLE) or Active, Refractory Lupus Nephritis (LN).
ClinicalTrials.gov Identifier:
Novartis Reference Number:CYTB323J12201
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN).

Lupus Erythematosus, Systemic, Lupus Nephritis
Phase2
Recruiting
179
Sep 04, 2024
Feb 06, 2032
All
18 Years - 75 Years (Adult, Older Adult)

Interventions

Biological

rapcabtagene autoleucel

single infusion of rapcabtagene autoleucel

Eligibility Criteria

Key Inclusion Criteria:

* Men and women with SLE, aged \>= 18 years and =\< 75 years at screening, fulfilling the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for SLE at screening.
* Participant must be positive for at least one of the following autoantibodies at screening: antinuclear antibodies (ANA) at a titer of \>= 1:80 (on HEp-2 cells or an equivalent positive test), or anti-dsDNA (above the ULN); or anti-Sm (above the ULN) as determined by a central laboratory.
* Active lupus nephritis without signs of significant chronicity or active systemic lupus erythematosus
* SLEDAI-2K Criteria at screening: SLEDAI-2K score \>= 6 points (Gladman et al 2002, Touma et al 2011), excluding points attributed to "fever", "lupus headache", "alopecia", and "organic brain syndrome".
* Inadequate response at screening to at least two therapies

Key Exclusion Criteria:

* Any acute, severe lupus related-flare at screening that needs immediate treatment other than pulse GCs and/or makes the immunosuppressive washout impossible and, thus, makes the participant ineligible for CD19 CAR-T therapy
* Inadequate organ function during screening and prior to randomization
* History or current diagnosis of ECG or cardiac abnormalities indicating significant risk of safety for participants prior to randomization
* Human immunodeficiency virus (HIV) positivity at screening.
* Acute or chronic infection with hepatitis B (HBV) or hepatitis C (HCV) at screening.
* Grade 2 or higher thromboembolic event in the past 4 weeks prior to screening.

Other protocol-defined inclusion/exclusion criteria may apply.

Novartis Investigative Site

Recruiting

Clayton,Victoria,3168,Australia

Novartis Investigative Site

Recruiting

Vienna,1090,Austria

Novartis Investigative Site

Recruiting

São Paulo,01509-010,Brazil

Novartis Investigative Site

Recruiting

São Paulo,São Paulo,01232-010,Brazil

Novartis Investigative Site

Recruiting

Salvador,Estado de Bahia,41253-190,Brazil

Novartis Investigative Site

Recruiting

Prague,128 00,Czechia

Novartis Investigative Site

Recruiting

Olomouc,779 00,Czechia

Novartis Investigative Site

Recruiting

Aarhus N,8200,Denmark

Novartis Investigative Site

Recruiting

Vandœuvre-lès-Nancy,54511,France

Novartis Investigative Site

Recruiting

Marseille,13005,France

Novartis Investigative Site

Recruiting

Paris,75014,France

Novartis Investigative Site

Recruiting

Nantes,44093,France

Novartis Investigative Site

Recruiting

Paris,75013,France

Novartis Investigative Site

Recruiting

Toulouse,31054,France

Novartis Investigative Site

Recruiting

Bordeaux,33076,France

Novartis Investigative Site

Recruiting

Essen,45147,Germany

Novartis Investigative Site

Recruiting

Jena,Thuringia,07740,Germany

Novartis Investigative Site

Recruiting

Nuremberg,90419,Germany

Novartis Investigative Site

Recruiting

Leipzig,Saxony,04103,Germany

Novartis Investigative Site

Recruiting

Mainz,55131,Germany

Novartis Investigative Site

Recruiting

Ulm,89081,Germany

Novartis Investigative Site

Recruiting

Budapest,H-1083,Hungary

Novartis Investigative Site

Recruiting

Pavia,PV,27100,Italy

Novartis Investigative Site

Recruiting

Milan,MI,20132,Italy

Novartis Investigative Site

Recruiting

Milan,MI,20122,Italy

Novartis Investigative Site

Recruiting

Genova,GE,16132,Italy

Novartis Investigative Site

Recruiting

Ancona,AN,60126,Italy

Novartis Investigative Site

Recruiting

Rozzano,MI,20089,Italy

Novartis Investigative Site

Recruiting

Pisa,PI,56126,Italy

Novartis Investigative Site

Recruiting

Sapporo,Hokkaido,060 8648,Japan

Novartis Investigative Site

Recruiting

Fukuoka,Fukuoka,812-8582,Japan

Novartis Investigative Site

Recruiting

Kobe,Hyōgo,650-0047,Japan

Novartis Investigative Site

Recruiting

Kanazawa,Ishikawa-ken,920 8641,Japan

Novartis Investigative Site

Recruiting

Sendai,Miyagi,980 8574,Japan

Novartis Investigative Site

Recruiting

Yokohama,Kanagawa,236-0004,Japan

Novartis Investigative Site

Recruiting

Suita,Osaka,565 0871,Japan

Novartis Investigative Site

Recruiting

Izumo,Shimane,693 8501,Japan

Novartis Investigative Site

Recruiting

Bunkyo Ku,Tokyo,113-8431,Japan

Novartis Investigative Site

Recruiting

Chiba,2608677,Japan

Novartis Investigative Site

Recruiting

Bunkyo-ku,Tokyo,113-8519,Japan

Novartis Investigative Site

Recruiting

Kyoto,606 8507,Japan

Novartis Investigative Site

Recruiting

Groningen,9713 gz,Netherlands

Novartis Investigative Site

Recruiting

Leiden,South Holland,2333 za,Netherlands

Novartis Investigative Site

Recruiting

Utrecht,3584 cx,Netherlands

Novartis Investigative Site

Recruiting

Oslo,0372,Norway

Novartis Investigative Site

Recruiting

Bucharest,022328,Romania

Novartis Investigative Site

Recruiting

Singapore,119074,Singapore

Novartis Investigative Site

Recruiting

Seoul,06591,South Korea

Novartis Investigative Site

Recruiting

Córdoba,14004,Spain

Novartis Investigative Site

Recruiting

Salamanca,Castille and León,37007,Spain

Novartis Investigative Site

Recruiting

Barcelona,Catalonia,08035,Spain

Novartis Investigative Site

Recruiting

Pamplona,Navarre,31008,Spain

Novartis Investigative Site

Recruiting

Santiago Compostela,A Coruna,15706,Spain

Novartis Investigative Site

Recruiting

Madrid,28009,Spain

Novartis Investigative Site

Recruiting

Madrid,28041,Spain

Novartis Investigative Site

Recruiting

Santander,Cantabria,39008,Spain

Novartis Investigative Site

Recruiting

Valencia,46026,Spain

Novartis Investigative Site

Recruiting

Stockholm,17176,Sweden

Novartis Investigative Site

Recruiting

Lausanne,1011,Switzerland

Novartis Investigative Site

Recruiting

Taipei,10002,Taiwan

Novartis Investigative Site

Recruiting

Taichung,407219,Taiwan

Novartis Investigative Site

Recruiting

London,W12 0hs,United Kingdom

Novartis Investigative Site

Recruiting

Sheffield,South Yorkshire,S10 2jf,United Kingdom

University of Texas MD Anderson Cancer Center

Recruiting

Houston,Texas,77030,United States

Maria Suarez-Almazor
Christle Joy Roan
Samer Srour

Northwestern University

Recruiting

Chicago,Illinois,60611,United States

Tyler Sorensen
Sonali Chaudhury
Matthew Selle
George Georges

LDS Hospital

Recruiting

Salt Lake City,Utah,84143,United States

Tara Sou
Catherine Jennifer Bakewell
Helen Azabache

UCSF

Recruiting

San Francisco,California,94115,United States

Bethany Bautista
Emily Von Scheven
Zilan Zheng

University Of Iowa

Recruiting

Iowa City,Iowa,52242,United States

Jackline Wangui
Hanna Zembrzuska

Boston Medical Center

Recruiting

Boston,Massachusetts,02118,United States

Brittany Fuller
Hanni Menn-Josephy

University of Kentucky

Recruiting

Lexington,Kentucky,40536-0284,United States

Natalie Jo Hawes
Paramarajan Piranavan

Oregon Health Sciences University

Recruiting

Portland,Oregon,97239,United States

Atul Deodhar
Issabell Melz

Sutter Health Network

Recruiting

San Pablo,California,94806,United States

Neftali Nevarez
Yomi Kapasi

Tufts Medical Center

Recruiting

Boston,Massachusetts,02111,United States

Andreas Klein
Kristina Yu

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Novartis Pharmaceuticals